Chronic Myeloid Leukemia

Deep Molecular Response to TKI Therapy Predicts Better Survival in CML

A deep molecular response to imatinib, achieved by most chronic myeloid leukemia patients who receive the drug, is predictive of better overall survival, according to a new study.

Chronic Myeloid Leukemia

STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.

Lymphocyte infusions are extremely effective therapy in patients with chronic myeloid leukemia who relapse after allogeneic hematopoietic stem cell transplantation, and the timing of the infusion is relatively unimportant, according to a new study.

Measuring changes in levels of BCR-ABL in patients with chronic myeloid leukemia (CML) can help predict treatment outcomes and disease progression, according to a new study.

A novel agent known as BL-8040 will enter phase I/II testing for the treatment of chronic myeloid leukemia, according to BioLineRx, the company developing the drug.

A rare subtype of disease known as atypical chronic myeloid leukemia (aCML) has been shown to be clinically distinct from a related condition known as unclassifiable myelodysplastic/myeloproliferative neoplasm.

Chronic myeloid leukemia

A subgroup of chronic myeloid leukemia (CML) cells that were “sticky,” or adherent to plastic, showed higher expression levels of BCR-ABL and were more resistant to treatment with the tyrosine kinase inhibitor imatinib.

MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.


Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.